First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

BACKGROUND: This phase 1 study examined the safety, maximum-tolerated dose (MTD) and antitumour activity of E7449, a novel PARP 1/2 and tankyrase 1/2 inhibitor. METHODS: E7449 was orally administered once daily in 28-day cycles to patients with advanced solid tumours (50–800-mg doses). Archival tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Plummer, Ruth, Dua, Divyanshu, Cresti, Nicola, Drew, Yvette, Stephens, Peter, Foegh, Marie, Knudsen, Steen, Sachdev, Pallavi, Mistry, Bipin M., Dixit, Vaishali, McGonigle, Sharon, Hall, Nancy, Matijevic, Mark, McGrath, Shannon, Sarker, Debashis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434893/
https://www.ncbi.nlm.nih.gov/pubmed/32523090
http://dx.doi.org/10.1038/s41416-020-0916-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434893/
https://www.ncbi.nlm.nih.gov/pubmed/32523090
http://dx.doi.org/10.1038/s41416-020-0916-5

Ejemplares similares